We at Auris Medical are dedicated to developing novel pharmaceutical products for the treatment of inner ear disorders and central nervous system disorders. We are focusing on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201). These programs have gone through two Phase 1 trials and will move into proof-of-concept studies in 2019. In addition, Auris Medical has two Phase 3 programs under development: SonsuviÂŽ (AM-111) for acute inner ear hearing loss and KeyzilenÂŽ (AM-101) for acute inner ear tinnitus. SonsuviÂŽ (AM-111) has been granted orphan drug status by the FDA and the EMA and has been granted fast track designation by the FDA. Source
No articles found.
RB is the global leading consumer health, hygiene and home company. Driven by a pu...
RB is the global leading consumer health, hygie...
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical...
Neurocrine Biosciences (Nasdaq: NBIX) is a neur...
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in ...
CNS Pharmaceuticals is a pre-clinical stage bio...
Opiant is a specialty pharmaceutical company developing medicines for addiction an...
Opiant is a specialty pharmaceutical company de...
We are a biopharmaceutical company dedicated to the development of programmed cell...
We are a biopharmaceutical company dedicated to...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a responsibly-driven company focused o...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a r...
Join the National Investor Network and get the latest information with your interests in mind.